CHMP Recommends Approval of Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation

Corporate Breaking News

Home : CHMP Recommends Approval of Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation

Jan 31 2022	CHMP Recommends Approval of Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation
TARRYTOWN, N.Y. and PARIS, Jan. 31, 2022 /PRNewswire/ -- Recommendation based on pivotal trial that showed Dupixent significantly reduced severe asthma attacks and improved lung function in children aged 6 to 11 years Dupixent is the only biologic to show improved lung function in a...


Source:https://www.prnewswire.com:443/news-releases/chmp-recommends-approval-of-dupixent-dupilumab-for-children-aged-6-to-11-years-with-severe-asthma-with-type-2-inflammation-301470938.html

Related News
» Organic Soap Market - 35% of Growth to Originate from North America\|Rising adoption of organic BPC products to Boost Market \|17000+ Technavio Reports » Digital Signature Market - 33% of Growth to Originate from North America \| Rising number of partnerships and acquisitions to Boost Market \| 17000+ Technavio Reports